Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1079 • 2014 ACR/ARHP Annual Meeting
Prevalence of Cardiac Arrhythmias in Systemic Lupus Erythematosus
Gihyun Myung¹, Lindsy J. Forbess², Mariko L. Ishimori², Sumeet Chugh¹, Daniel Wallace¹ and Michael H. Weisman¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose Cardiovascular disease is a major cause of death among systemic lupus erythematosus (SLE) patients. Although the prevalence of atrial fibrillation (0.5-1%) and QT prolongation…
Abstract Number: 873 • 2014 ACR/ARHP Annual Meeting
The Second Messenger, Cyclic GMP-AMP Dinucleotide (cGAMP) and the Enzyme, Cyclic GMP-AMP Synthase (cGAS), Are Expressed in Systemic Lupus Erythematosus
Jie An¹, Joshua Woodward², Reynold Karr³, Thomas H. Teal⁴ and Keith B. Elkon¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Medicine, University of Washington, Seattle, WA, ⁴Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The type I IFNs (IFN-I), are strongly associated with Systemic Lupus Erythematosus (SLE). It is generally considered that IFN-I is induced by immune complexes…
Abstract Number: 700 • 2014 ACR/ARHP Annual Meeting
Decreased Lung Diffusion Capacity in Asymptomatic Patients with Systemic Lupus Erythematosus Does Not Predict Future Lung Disease
Ofir Elalouf¹, Elizabeth Fireman², David Levartovsky¹, Ilana Kaufman¹, Ori Rogovski³, Ori Elkayam¹, Dan Caspi¹ and Daphna Paran¹, ¹Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Pulmonary and Allergic diseases, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³Internal Medicine ward, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Background/Purpose In a previous study, performed 9±3.6 years ago 74 asymptomatic patients with systemic lupus erythematosus (SLE) and or antiphospholipid syndrome (APS) who fulfilled the…
Abstract Number: 697 • 2014 ACR/ARHP Annual Meeting
Venous and Arterial Thrombosis in SLE: Differences in Natural History
Katharine Hickman¹, Laurence S. Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Thrombosis is increased in SLE due to disease activity and co-morbid factors including antiphospholipid antibodies. We separately investigated the natural history of venous vs.…
Abstract Number: 689 • 2014 ACR/ARHP Annual Meeting
Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)
Khaled Alderaan¹, Vuk Sekicki², Laurence S. Magder³ and Michelle Petri⁴, ¹King Fahad Specilaist Hospital, Dammam, Saudi Arabia, ²Medicine, Saint Agnes Hospital, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cataract is the most common ocular damage in SLE. It is the second most frequent item in the SLICC/ACR Damage Index. Apart from cumulative…
Abstract Number: 2675 • 2014 ACR/ARHP Annual Meeting
The Selective Loss of SLAMF4⁺ CD8⁺ T Cells Contributes to the Decreased Cytotoxic Capacity Observed in Systemic Lupus Erythematosus
Katalin Kis-Toth¹, Denis Comte¹, Maria Karampetsou¹, Lakshmi Kannan² and George C. Tsokos¹, ¹Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²Rheumtology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose Signaling lymphocytic activation molecule family member 4 (SLAMF4) engagement by its ligand SLAMF2 can mediate the cytotoxicity of CD8+ T cells and natural killer…
Abstract Number: 677 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Biological Activity of Intravenously or Subcutaneously Administered Tabalumab in Subjects with Rheumatoid Arthritis or Systemic Lupus Erythematosus
Jennifer Witcher¹, Ryan Hansen¹, Leijun Hu¹, David Radtke¹, James Voelker¹ and Juliet McColm², ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Windlesham, United Kingdom
Background/Purpose : B-cell activating factor (BAFF) promotes B-cell survival and maturation, and increased serum levels are associated with autoimmune disease and disease activity in systemic…
Abstract Number: 2674 • 2014 ACR/ARHP Annual Meeting
The Effect and Mechanisms of Icaritin on Regulating Foxp3/IL17a Expression in CD4⁺ T Cells from SLE
Jieyue Liao¹, Yu Liu², Ming Zhao³, hai Jing Wu⁴ and Qianjin Lu⁵, ¹Department of Dermatology, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Dermatology, Second Xiangya Hospital, Central South University, shangcha, China, ³Department of Dermatology, Second Xiangya Hospital, Central South University, changsha, China, ⁴Department of Dermatology, Second Xiangya Hospital, Central South University, sahngsha, China, ⁵Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose : Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease characterized by overproduction of autoantibodies. The pathogenesis of SLE is complex. Several studies…
Abstract Number: 2689 • 2014 ACR/ARHP Annual Meeting
The CUL4^CRBN E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus
Peter H. Schafer¹, Ying Ye², Lei Wu³, Jolanta Kosek⁴, Zhihong Yang⁵, Liangang Liu⁵, Michael Thomas⁵, Maria Palmisano⁵ and Rajesh Chopra⁵, ¹Celgene Corporation, Celgene Corporation, Summit, NJ, ²86 Morris Avenue, Celgene Corporation, Summit, NJ, ³Department of Translational Development, Celgene Corporation, Summit, NJ, ⁴Translational Development, Celgene Corporation, Summit, NJ, ⁵Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is an immunomodulatory compound that binds to cereblon (CRBN), part of the CUL4CRBN E3 ubiquitin ligase complex, which has been shown to ubiquitinate…
Abstract Number: 2667 • 2014 ACR/ARHP Annual Meeting
First-Trimester Disease Activity Does Not Predict Pre-Eclampsia in SLE Pregnancy
Khaled Alderaan¹, Laurence S. Magder² and Michelle Petri³, ¹King Fahad Specilaist Hospital, Dammam, Saudi Arabia, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Preeclampsia complicates up to 35% of lupus pregnancies compared to 8% of general population pregnancies. SLE has up to a 3-fold increased rate of…
Abstract Number: 2635 • 2014 ACR/ARHP Annual Meeting
Noncalcified Plaque Progression in Systemic Lupus Erythematosus
Adnan Kiani¹, Armin Zadeh², Joao Lima², Laurence S. Magder³ and Michelle Petri⁴, ¹1830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Coronary atherosclerosis is a major cause of morbidity and mortality in SLE. New technology, computed tomoangiography (CTA) can measure non-calcified coronary plaque (NCP),…
Abstract Number: 2648 • 2014 ACR/ARHP Annual Meeting
Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Xiangyang Huang¹, Laurence S. Magder² and Michelle Petri³, ¹Sichuan University School of Medicine, Sichuan, China, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Depression affects as many as 30% of SLE patients. Most studies of risk factors for depression among SLE patients have been cross-sectional, and thus…
Abstract Number: 2738 • 2013 ACR/ARHP Annual Meeting
Microrna-Mediated Regulation Explains Allelic Risk Of TLR7 Variant Predisposing To Systemic Lupus Erythematosis
Yun Deng¹, Jian Zhao¹, Jennifer M. Grossman² and Betty P. Tsao¹, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: We identified a genome-wide significant association of the TLR7 variant (rs3853839) with SLE susceptibility in multiple ancestries (Pmeta =2.0×10-19, OR =1.25), and the risk…
Abstract Number: 2505 • 2013 ACR/ARHP Annual Meeting
Higher Disease Damage Among African Americans With Familial Versus Sporadic Systemic Lupus Erythematosus
April Barnado¹, Lee Wheless², Stephanie Slan¹, Gary S. Gilkeson¹ and Diane L. Kamen¹, ¹Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Public Health Sciences, Medical University of South Carolina, Charleston, SC
Background/Purpose: Studies in predominantly Caucasian cohorts have found no significant clinical or serologic differences in systemic lupus erythematosus (SLE) patients with a family history of…
Abstract Number: 1583 • 2013 ACR/ARHP Annual Meeting
Serositis In Systemic Lupus Erythematosus: Prevalence, Recurrence, Treatment and Outcome
Mansour Somaily¹, Dafna D. Gladman², Dominique Ibanez² and Murray B. Urowitz², ¹Medicine, Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Serositis is one of the ACR classification criteria for SLE. Its incidence is variable in studies varying from 12 to 60%. The aim of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].